Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Jasper Therapeutics Inc (JSPRW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/26/2025: JSPRW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.71% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/26/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.73 | 52 Weeks Range 0.06 - 0.25 | Updated Date 05/31/2025 |
52 Weeks Range 0.06 - 0.25 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.5% | Return on Equity (TTM) -101.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9908441 |
Shares Outstanding - | Shares Floating 9908441 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Jasper Therapeutics Inc
Company Overview
History and Background
Jasper Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of gene therapies and stem cell transplantation therapies. It was founded in 2016 and went public via SPAC merger in 2022. The company is named after jasper, a gemstone known for its healing properties.
Core Business Areas
- Stem Cell Transplantation: Develops conditioning agents for stem cell transplantation to improve outcomes for patients with hematologic malignancies and genetic diseases.
- Gene Therapy: Focuses on enabling safer and more effective gene therapy by developing novel conditioning agents to facilitate gene editing.
Leadership and Structure
The leadership team includes Ronald Martell (CEO), Edwin Klumper (CFO), and Dr. Judith Shizuru (Chief Medical Officer). The organizational structure is typical of a biotechnology company, with departments dedicated to research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Bucosalfan: Bucosalfan is an investigational targeted conditioning agent. Market share data is not publicly available. Competitors include established chemotherapy regimens and other emerging conditioning agents in development.
Market Dynamics
Industry Overview
The biotechnology industry is rapidly evolving, with significant advancements in gene therapy and stem cell transplantation. This market is competitive and highly regulated, with substantial investment in research and development.
Positioning
Jasper Therapeutics is positioned as a developer of novel conditioning agents for stem cell transplantation and gene therapy, aiming to improve safety and efficacy compared to existing treatments.
Total Addressable Market (TAM)
The total addressable market for conditioning agents in stem cell transplantation and gene therapy is estimated to be in the billions of dollars. Jasper Therapeutics is positioned to capture a share of this market by developing innovative products.
Upturn SWOT Analysis
Strengths
- Novel conditioning agent technology
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on clinical trial success
- Limited commercialized products
- High cash burn rate
Opportunities
- Expanding applications of gene therapy
- Partnerships with pharmaceutical companies
- Advancements in stem cell transplantation
Threats
- Regulatory hurdles
- Competition from established therapies
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- BMY
- GSK
- SAN
Competitive Landscape
Jasper Therapeutics faces competition from established pharmaceutical companies with existing therapies and other biotechnology companies developing novel conditioning agents. Its competitive advantage lies in its targeted conditioning agent technology.
Growth Trajectory and Initiatives
Historical Growth: Historical revenue data is limited as the company is pre-commercialization.
Future Projections: Future growth is dependent on clinical trial outcomes and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing the clinical development of bucosulfan and exploring partnerships for gene therapy applications.
Summary
Jasper Therapeutics is a pre-commercial biotechnology company focused on stem cell transplantation and gene therapy conditioning agents. Its success hinges on the outcomes of clinical trials for Bucosalfan. While it has innovative technology, the company faces significant regulatory and financial risks. It competes against larger, established companies with existing market presence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may be subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-01-10 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://jaspertx.com |
Full time employees 64 | Website https://jaspertx.com | ||
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.